Targeted Deletion of Angiotensin Ii Type 1a Receptor Does Not Protect Mice from Progressive Nephropathy of Overload Proteinuria

In experimental and human renal diseases, progression is limited by angiotensin-converting enzyme inhibitors. Whether renoprotection was due to their capacity of reducing proinflammatory and profibrotic effects of angiotensin II (Ang II) or limiting proteinuria and its long term toxicity is debated. For dissecting the relative contribution of Ang II and proteinuria to chronic renal damage, the protein-overload proteinuria model was used in genetically modified mice lacking the major isoform of murine AT1 receptor (AT1A). Uninephrectomized AT1A+/+ and -/- mice received a daily injection of BSA or saline for 4 or 11 wk. AT1A-/-BSA mice acquired a renal phenotype of proteinuria and renal glomerular and tubulointerstitial lesions, albeit attenuated with respect to AT1A+/+BSA. Administration of the calcium channel blocker lacidipine to reduce BP of AT1A+/+BSA mice to levels of AT1A-/-BSA translated into comparable values of protein excretion rate and glomerular and tubulointerstitial injury in both strains. These results confirm that the toxic effect of protein trafficking on renal disease progression is not necessarily dependent on Ang II to the extent that targeted deletion of AT1A does not prevent disease progression. A role of Ang II via AT1B or AT2 receptors is still a possibility that cannot be ruled out by the present experimental approach. These findings provide a clear rationale for specifically targeting proteinuria in pharmacologic interventions of chronic nephropathies.

[1]  H. Matsubara,et al.  Overexpression of angiotensin type 2 receptor ameliorates glomerular injury in a mouse remnant kidney model. , 2004, American journal of physiology. Renal physiology.

[2]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[3]  M. Cooper,et al.  Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. , 2003, Journal of the American Society of Nephrology : JASN.

[4]  A. Ortiz,et al.  Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. , 2003, Kidney international. Supplement.

[5]  G. Remuzzi,et al.  Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor kappaB- and p38 mitogen-activated protein kinase-dependent pathways. , 2003, Journal of the American Society of Nephrology : JASN.

[6]  R. Carey,et al.  Angiotensin AT2 Receptors Directly Stimulate Renal Nitric Oxide in Bradykinin B2-Receptor–Null Mice , 2003, Hypertension.

[7]  B. Brenner Retarding the progression of renal disease. , 2003, Kidney international.

[8]  G. Remuzzi,et al.  Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. , 2003, Kidney international.

[9]  G. Remuzzi,et al.  Proteinuria and phenotypic change of proximal tubular cells. , 2003, Journal of the American Society of Nephrology : JASN.

[10]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[11]  N. Perico,et al.  Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. , 2003, Kidney international.

[12]  K. Chan,et al.  Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. , 2003, The Journal of clinical investigation.

[13]  N. Perico,et al.  New therapeutics that antagonize endothelin: promises and frustrations , 2002, Nature Reviews Drug Discovery.

[14]  G. Remuzzi,et al.  Effect of high dose ramipril with or without indomethacin on glomerular selectivity. , 2002, Kidney international.

[15]  M. Cooper,et al.  Materials and Methods Protocol 1 : Assessment of AT 1 and AT 2 Receptor Expression in the Remnant Kidney , 2002 .

[16]  G. Wolf "The road not taken": role of angiotensin II type 2 receptor in pathophysiology. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  F. Luft,et al.  Lacidipine Inhibits Adhesion Molecule and Oxidase Expression Independent of Blood Pressure Reduction in Angiotensin-Induced Vascular Injury , 2002, Hypertension.

[18]  K. Griffin,et al.  Long-term renal consequences of hypertension for normal and diseased kidneys , 2002, Current opinion in nephrology and hypertension.

[19]  T. Sugaya,et al.  Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1. , 2001, The American journal of pathology.

[20]  K. Bernstein,et al.  Genetic manipulation of the renin-angiotensin system , 2001, Current opinion in nephrology and hypertension.

[21]  G. Remuzzi,et al.  Progression, remission, regression of chronic renal diseases , 2001, The Lancet.

[22]  Yusuke Suzuki,et al.  Proinflammatory actions of angiotensins , 2001, Current opinion in nephrology and hypertension.

[23]  R. Witzgall,et al.  Update in podocyte biology , 2001, Current opinion in nephrology and hypertension.

[24]  A. Fogo,et al.  Progression and potential regression of glomerulosclerosis. , 2001, Kidney international.

[25]  F. Terzi,et al.  Using transgenic mice to analyze the mechanisms of progression of chronic renal failure. , 2000, Journal of the American Society of Nephrology : JASN.

[26]  C. Zancanaro,et al.  The calcium‐channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE‐deficient mouse , 2000, Journal of hypertension.

[27]  P. Soloway,et al.  Interstitial fibrosis in mice with overload proteinuria: deficiency of TIMP-1 is not protective. , 2000, Kidney international.

[28]  D. Ganten,et al.  Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. , 2000, Hypertension.

[29]  G. Bakris,et al.  SPECIAL REPORT Preserving Renal Function in Adults With Hypertension and Diabetes: A Consensus Approach , 2000 .

[30]  T. Hostetter,et al.  The course of the remnant kidney model in mice. , 1999, Kidney international.

[31]  H. S. Kim,et al.  Reduced growth, abnormal kidney structure, and type 2 (AT2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Coresh,et al.  Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[33]  G. Remuzzi,et al.  Pathophysiology of progressive nephropathies. , 1998, The New England journal of medicine.

[34]  G. Remuzzi,et al.  Novel strategies to retard renal disease progression: combining ACE inhibition with endothelin receptor blocking? , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  G. Bakris,et al.  Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. , 1998, Kidney international.

[36]  J. Egido,et al.  Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. , 1998, Journal of immunology.

[37]  G. Remuzzi,et al.  Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. , 1998, Kidney international.

[38]  T. Inagami,et al.  Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. , 1998, Kidney international.

[39]  G. Remuzzi,et al.  Angiotensin II Blockade Limits Tubular Protein Overreabsorption and the Consequent Upregulation of Endothelin 1 Gene in Experimental Membranous Nephropathy , 1998, Nephron Experimental Nephrology.

[40]  G. Remuzzi,et al.  Understanding the nature of renal disease progression. , 1997, Kidney international.

[41]  N. Perico,et al.  Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. , 1996, Journal of the American Society of Nephrology : JASN.

[42]  M. Horiuchi,et al.  Angiotensin II type 2 receptor mediates programmed cell death. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Hodgin,et al.  A noninvasive computerized tail-cuff system for measuring blood pressure in mice. , 1995, Hypertension.

[44]  P. Mannon,et al.  Regulation of blood pressure by the type 1A angiotensin II receptor gene. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[45]  C. Sigmund,et al.  Differential expression of angiotensin receptor 1A and 1B in mouse. , 1994, The American journal of physiology.

[46]  S. Kagami,et al.  Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. , 1994, The Journal of clinical investigation.

[47]  S. Kuroda,et al.  Novel subtype of human angiotensin II type 1 receptor: cDNA cloning and expression. , 1994, Biochemical and biophysical research communications.

[48]  P. Timmermans,et al.  Angiotensin II receptors and angiotensin II receptor antagonists. , 1993, Pharmacological reviews.

[49]  B. Kobilka,et al.  Cloning, characterization, and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome. , 1992, Biochemical and biophysical research communications.

[50]  K. Catt,et al.  Cloning and expression of a novel angiotensin II receptor subtype. , 1992, The Journal of biological chemistry.

[51]  N. Perico,et al.  Increased renal endothelin production in rats with reduced renal mass. , 1991, The American journal of physiology.

[52]  G. Remuzzi,et al.  Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. , 1990, The Journal of clinical investigation.